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Background: High levels of adherence to medications for HIV infection are essential for optimal clinical outcomes
and to reduce viral transmission, but many patients do not achieve required levels. Clinician-delivered interventions
can improve patients’ adherence, but usually require substantial effort by trained individuals and may not be widely
available. Computer-delivered interventions can address this problem by reducing required staff time for delivery
and by making the interventions widely available via the Internet. We previously developed a computer-delivered
intervention designed to improve patients’ level of health literacy as a strategy to improve their HIV medication
adherence. The intervention was shown to increase patients’ adherence, but it was not clear that the benefits
resulting from the increase in adherence could justify the costs of developing and deploying the intervention. The
purpose of this study was to evaluate the relation of development and deployment costs to the effectiveness of
the intervention.
Methods: Costs of intervention development were drawn from accounting reports for the grant under which its
development was supported, adjusted for costs primarily resulting from the project’s research purpose. Effectiveness
of the intervention was drawn from results of the parent study. The relation of the intervention’s effects to changes
in health status, expressed as utilities, was also evaluated in order to assess the net cost of the intervention in terms
of quality adjusted life years (QALYs). Sensitivity analyses evaluated ranges of possible intervention effectiveness and
durations of its effects, and costs were evaluated over several deployment scenarios.
Results: The intervention’s cost effectiveness depends largely on the number of persons using it and the duration
of its effectiveness. Even with modest effects for a small number of patients the intervention was associated with
net cost savings in some scenarios and for durations greater than three months and longer it was usually
associated with a favorable cost per QALY. For intermediate and larger assumed effects and longer durations of
intervention effectiveness, the intervention was associated with net cost savings.
Conclusions: Computer-delivered adherence interventions may be a cost-effective strategy to improve adherence
in persons treated for HIV.
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Although advances in combination antiretroviral therapy
(cART) have had a huge impact on the effectiveness of
treatment for HIV infection, treatment regimens continue
to require high levels of adherence. Studies of medication
adherence in persons treated for HIV infection, however,
show that many affected individuals do not achieve the
levels of adherence needed for optimal treatment outcomes
[1,2]. Social psychological theories of health behavior have
been used to develop interventions to promote adherence,
and many have been successful. Theories such as
Information-Motivation-Behavioral Skills model, [3] the
Health Belief Model, [4] and the Theory of Planned Behav-
ior [5] as well as empirical research on factors associated
with poor adherence have been the basis for various effect-
ive interventions [6,7]. These interventions have often
targeted individuals’ beliefs or knowledge about the disease
or its treatment, but have also targeted factors that inter-
fere with adherence, such as depression [8].
Although effective interventions exist, they are not widely
available. Even brief clinician-delivered interventions may be
beyond the reach of many patients. Interventions for adher-
ence are clearly a part of standard care for HIV infection [9]
and it is likely that standard interventions may have a posi-
tive effect on patients’ adherence [10]. It is not clear, how-
ever, whether adherence interventions are routinely
provided in regular clinical care. It is likely that a great deal
of clinician-delivered adherence counseling is delivered in
the context of hurried clinical visits during which other
medical concerns must also be addressed [11]. This strategy
may be less than optimal, especially in light of research that
has shown that patients may remember as little as little as
50% of orally-presented information [12,13] and that mem-
ory for information provided by clinicians is related to
age, education, and gender [14]. Few clinicians are likely to
have the time to spend one hour providing individually-
tailored information or to have the therapeutic skills to
address common concerns such as substance abuse or
depression as in the intervention used in this study [15] (see
Additional file 1).
Computer-delivered interventions, although expen-
sive to develop, may be delivered at low cost on existing
computers and over the Internet on mobile devices. A
number of electronic interventions have been shown to
be efficacious in improving medication adherence [16],
and one recent trial showed that a computer-delivered
intervention provided in a clinic was effective in im-
proving medication adherence in patients treated for
HIV [17].
Electronically-delivered interventions have a number of
potential advantages over clinician-delivered interventions.
The ongoing cost of maintaining an application on local
computers or a server can be low, and computer-based
interventions may be able to implement substantiallysimilar interventions with much smaller investments of
clinician time. By doing so, busy clinicians may be released
from routine educational duties to cope with more com-
plex problems that demand their attention. It is possible
that if such an intervention were routinely available
clinicians might spend less time in adherence counseling
with patients. A computer-delivered intervention would
not replace clinician efforts, but reduce the demands on
their time made by routine educational tasks and allow
them to provide critically important interventions to
patients. Further, existing data on computer-based infor-
mation resources have shown that improved access to in-
formation may have a positive effect on patient knowledge
and ability to interact with physicians [18]. Electronically-
delivered interventions provided on the Internet can be
available in real time to patients as they are needed or as
patients have the opportunity to consult them.
It could thus support clinicians’ work with these
patients and even empower patients to work more ac-
tively with clinicians. Intensive interventions requiring
multiple sessions and substantial clinician time, for ex-
ample, may cost as much as $4,000 per year per patient
[19]. Even with the costs of clinician-delivered adherence
interventions, the interventions may actually reduce
total net costs [19] but in spite of cost savings adherence
interventions may not be widely deployed because
of lack of trained personnel. Further, adherence
interventions may be difficult to deliver to persons in
rural areas due to the need to travel long distances in
order to receive treatment [20].
We developed a computer-delivered adherence inter-
vention that focused on improving participants’ HIV-
related health literacy as a strategy to increase their
medication adherence. The hour-long intervention was
delivered on stock touch screen computers (Hewlett-
Packard TouchSmart series; Palo Alto, California) and
only required that participants interact with it by
touching large buttons on the computer screen. In order
to keep development costs to a minimum, the interven-
tion utilized low-cost or free media and was developed
in off-the-shelf software used for computer training and
simulation (CaptivateW, Adobe Corporation, San Jose,
California).
Content for the intervention was first developed by
reviewing popular patient education materials available
commercially, online, and from advocacy organizations.
The materials were then reviewed by a multidisciplinary
team that included physicians, nurses, psychologists, a
pharmacist, and a social worker. Resulting content was
organized into concept-based sections that focused on
basic information about viral replication and transmis-
sion, on mechanisms of drug action, use and interpret-
ation of laboratory values, the meaning of 95%
adherence, factors related to motivation (such as coping
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maintaining adherence. Participants in the study
completed the intervention in a single session that
required approximately one hour.
Consistent with cognitive load theory [21-23] and
principles of multimedia education [24], material was
presented in small segments (e.g., one portion of the
viral life cycle) and followed by assessing participant
understanding through multiple choice questions. To
enhance learner engagement and learning and re-
duce demands on literacy skills, material was presented
in short passages of text supported by pictures,
illustrations, and an animation supplemented with narra-
tion played on the computer’s speakers. When a partici-
pant failed to answer an assessment question correctly,
the material was immediately retaught after displaying a
personalized message employing the participant’s first
name and a statement such as “That’s not quite it. Let’s
go over that again.” All material with the exception of
technical terms such as “protease inhibitor” was
presented at a sixth grade reading level (Flesch-Kincaid
readability formula as implemented in Microsoft
WordW). Interactions with the computer only required
that participants tap on the computer screen, thus
keeping computer skills required to a minimum.
The computer-based intervention was first developed
via expert consensus on content and format and then
tested for its usability and acceptability with several
groups of potential users. After several rounds of assess-
ment and revision, the intervention was judged accept-
able by patients and was used in the study. Participants
completed the intervention in a single one-hour session.
It was intended for use by patients at any point in their
treatment although it might be most useful for patients
beginning treatment. Although it was developed as an
intervention to be reviewed once, in future research we
will evaluate how long its effects on intervention persist
and will consider development of a booster or review
intervention designed to target maintenance of high
levels of adherence.
More detailed information on the intervention and its
effectiveness is available in a paper [15] and a presenta-
tion with illustrations of the intervention computer set
up and example screens from the intervention itself is
available online [25]. A supplement to this paper
includes illustrations of screens viewed by participants in
the study of the intervention Additional file 1.
The intervention’s effects on adherence were assessed
using an electronic pill bottle that automatically
recorded the date and time of each opening (Medication
Event Monitoring System, or MEMS; Aardex, Ltd, Sion,
Switzerland), providing an evaluation of adherence for
the month before and the month after participants
completed the intervention. Although the MEMS systemis not a perfect measure of adherence, previous studies
have shown that the MEMS index is closely related to
viral load [26]. Participants’ demographic information
(age, education, race, gender), psychosocial status on
such variables as social support and depression, and cog-
nitive functioning were assessed at the time of study en-
rollment, allowing us to take these variables into
account in understanding participants’ response to the
intervention. Results based on 118 participants who
completed the intervention and follow-up visits (of a
total of 124 who entered the study and 120 who
completed the intervention) showed that participants
with less than 85% adherence (mean model-adjusted
baseline adherence was 58%) at baseline improved their
adherence an average of 10% [15]. While a modest
absolute change in behavior, the observed change
represented a medium effect size consistent with other
clinician-delivered interventions to improve adherence
[27] and was similar in magnitude to that observed in a
study of another computer-delivered intervention for
older persons with memory impairments [28]. Given the
possibility that computer-delivered interventions may
have effects similar to those of interventions that make
greater demands on clinician time, may cost more to
develop, but be more readily deployed to a large audi-
ence, a determination of the cost-effectiveness of the
computer-delivered intervention was judged important.
The purpose of this study was to assess the cost effect-
iveness of a computer-delivered intervention targeting
health literacy and adherence in persons treated for HIV
infection.Method
Overview
In this study, the costs of developing the intervention
were known and adjusted from the actual costs of the
research grant to take into account purely research-
related expenses. Costs of deploying the intervention
were calculated in two formats (as an information kiosk
in a clinic or office and as a web-based application avail-
able on computers or mobile devices) and under two
possible levels of utilization. All analyses were completed
from the societal perspective (taking into account all
total economic costs and benefits without regard for
payer). Figure 1 provides an overview of factors related
to costs involved in treating patients with HIV and their
quality of life as health utilities (left portion of figure),
the costs of developing and deploying the computer-
based intervention (top portion of figure) and the effects
of the intervention on treatment costs and quality of life
as health utilities (right portion of figure). A list of the
sources of the estimates used in analyses is provided in
Table 1.
Figure 1 Overview of cost effectiveness analysis.
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limited by lack of precise data on how changes in medi-
cation adherence might affect participants’ health costs
or status. Data on healthcare-related costs could not be
drawn from the parent study of the intervention as the
scope of the original project did not allow this informa-
tion to be collected, and data on adherence-related
health status could not be drawn from the parent study
due to its short duration. Data are available from other
sources, however, on costs and health state utilities
associated with CD4 count ranges [29,30] and the effects
of adherence on viral load and CD4 counts [31]. These
were used to calculate a Markov model of changes in
health costs and utilities resulting from increases in ad-
herence resulting from patients’ exposure to the inter-
vention (see Figure 2). As estimates of CD4 count
changes in response to the intervention vary widely and
were not available in our data, a range of possible effects
of the intervention were evaluated with respect to
changes in costs and utilities (Table 2).
In a cost effectiveness analysis, total costs of the inter-
vention (development and deployment costs adjusted for
changes in health care expenses) were evaluated for the
two deployment formats with two levels of utilization. In
a cost-utility analysis, likely change in health state util-
ities due to increased adherence were estimated and
used to calculate the cost of the intervention per
quality-adjusted life year (QALY).Costs
Costs were calculated in two ways in order to allow evalu-
ation of a range of possibilities. As the project was
supported by a grant, a precise account of all expenditures
in relation to the development and testing of the interven-
tion was available. Costs of staff salary, payments to
participants, and administrative overhead are listed in
Table 3. Costs were calculated as a portion of the total pro-
ject costs, as the total expenditures under the grant were
larger than those that would have otherwise been required
due to its research purpose. Some costs in this second esti-
mate are reduced to reflect more accurately development
costs in a non-research setting. Costs therefore were
reduced by the amounts of participant payments for base-
line and follow-up visits as these might not have occurred
in a commercial development setting and the amounts
budgeted for presentation of research results at profes-
sional meetings and compensation paid to a research
consultant.
Lost salary and wages
Development costs were increased to reflect participants’
lost salary and wages resulting from time taken off from
work to participate in the visit during which they
completed the intervention. This estimate of total devel-
opment costs was used in subsequent calculations.
Economic costs of lost wages to participants were
calculated based on the mean annual wage for each
Table 1 Sources of estimates used in analysis
Estimate Source Effect of intervention
Treatment Costs
Cost of Medications Based on participants’ actual antiretroviral regimens with
costs based on current average prices in 2012[39]. The
average annual cost per patient if fully adherent was
$22,675.
Increased use of medications because of
increased adherence increases costs of
medications
Inpatient and Outpatient Treatment by CD4
count
Based on data from Gebo et al. [30] adjusted to 2012
dollars reduced by medication costs that were calculated
directly (above). Costs vary by patient CD4 count, with
an overall average annual cost of $13,296
Improved health may increase cheaper
outpatient care use but decrease more
expensive inpatient care
Development Costs
Salary, Wages, Software, Consultants, Hardware,
Space, Media, Testing, Test Deployment for
study
Actual costs as recorded in records of grant expenditures
(detailed in Table 3)
Costs to participants during development Loss of salary and wages – estimate of lost salary and
wages by participants who reported working based on
their education level [32].
Cost of transportation -- from actual participant
reimbursement during development ($5.00 for daily bus
fare in our area).
Deployment costs – Office Kiosk Scenario
Space, computers, maintenance, staff,
electricity
Cost of office space from based on industry report [36]
Cost of computer purchase, operation, and maintenance
based on industry report [35]
Staff time costs based on average hourly wage for
medical assistant plus fringe benefits and administrative
costs (from US Bureau of Labor Statistics and institutional
fringe benefit and administrative cost rates)
Software License Nominal fee assumed to defray costs of duplication of
media and shipping (assumption)
Transportation for rural patients Average distance for rural patients to visit specialist
practitioner from Rosenthal et al. [37] and average cost
per mile of transportation [38] via mid-size sedan per the
American Automobile Association
Lost salary and wages Based on estimates obtained during development for
representative number of patients based on time lost
and salary calculated from participants’ educational
status [32]
Cost of computer and high speed Internet
access at home
Considered to be part of patients’ regular cost of living,
as the actual cost of one hour of computer and Internet
usage is small
Deployment costs – Web Deployment
Scenario
Server operation and maintenance Page et al. 2012 [44].
Advertising Page et al. 2012 [44]; amount increased for larger
number of users
Technical Support Page et al. 2012 [44].
Utilities
Numeric value of a specific health status (more
or less ill) based on immune function reflected
in CD4 (immune cell) count
Kauf et al. 2008 [29]. Improved adherence will improve
immune function and thus health status,
enhance patients’ quality of life
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reported working outside the home for pay. Twenty-two
participants reported working for pay outside the home,
and lost wages were calculated for two hours (one hour
for the intervention and one hour average time for theround trip from work or residence to the study site).
Total lost wages for the study was $742. This amount
was included in estimates of the total cost of developing
the intervention. Participants were compensated for
their effort in developing the intervention at the rate of
Figure 2 Utilities and costs for health states defined by CD4 counts. Note: Each expression labeled “p(t)” corresponds to a probability drawn
from the effectiveness scenarios listed in Table 2. For example, element p(t) for x1 (the probability that the intervention would be associated with
an increase in CD4 causing movement of patients from one group to another) would be 5% for the minimally effective scenario (first line of
Table 2).
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study visit during which they completed the intervention
is also included as part of total development costs.
Administrative costs
The administrative costs charged to the grant were based
on the negotiated rate between our university and the US
government and included to represent the administrative
overhead involved in the development process. These re-
flect the costs of providing office space, utilities, and ad-
ministrative support for the development project.
Deployment costs
An important factor in understanding the cost-effectiveness
of computer-delivered interventions is that while initial de-
velopment costs may be large compared to clinician-
delivered interventions, their subsequent deployment canTable 2 Probability change scenarios
Probability of change in disease state
Effectiveness of Intervention p(t) x1 p(t) x2
Minimally 5% 0%
Slightly 5% 1%
Moderately 10% 5%
Highly 20% 10%
Note: Each p represents an assumed probability that the intervention would increas
CD4 group (see Figure 2). The expression t in parentheses indicates that the probab
four possible transitions is represented. For the minimally effective scenario, the pro
person in the lower group might move to the next higher group. The average colu
used for estimation of changes in costs and utilities.readily make them widely available at low cost. The costs of
deployment of the intervention for routine use in clinical
practice, both in the form it was developed (information
kiosk style application on a touch screen computer) and on
the Internet (on a server with the application accessible to a
wider audience, including advertising costs) were therefore
estimated.
For the office-based information kiosk scenario, costs
were estimated based on two scenarios of the frequency of
intervention use. One estimate (low use office) was based
on estimates of the percentage of new patient ambulatory
care visits (assuming all patients were treated for HIV and
all would receive the intervention). A second estimate
(high office) was based on percentage of all ambulatory
care visits that involve health education. Based on an aver-
age number of patients per seen day of approximately 30
[33] and on data showing that 15% of office visits are forfrom lower CD4 range to next higher (see Figure 2)
p(t) x3 p(t) x4 Average
0% 0% 1%
0% 0% 2%
5% 0% 5%
5% 0% 9%
e a patient’s CD4 count sufficiently that they would move to the next higher
ility refers to a transition, while each x with a subscript indicates which of the
bability represented as “p(t) x1” thus indicates that there is a 5% chance that a
mn is the mean of the probabilities for each possible change in CD4 and was
Table 3 Adjusted development costsa
Salaries $152,323
Fringe $39,909
Total Salaries $192,232
Participant Payments $6,584
Participants’ Lost Wages $742
Supplies, Equipment, Computers $4,647
Software $500
Total Direct Costs $204,704
Administrative Support Costs @ 44.8% of Total Costs $76893
Total Development Costs $296,411
aTotal costs of project reduced for costs specific to research, including costs of
research consultant and participant visits only related to research.
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patients seen per day in a clinical office might be eligible
for the computer-based intervention. Conversely, data
show that 40.3% of ambulatory care visits include
provision of health education [34], from this perspective
suggesting that as many as 12 patients per day (of 30 seen)
might be eligible for the computer intervention. The num-
ber of visits eligible for the computer-based intervention
under both scenarios for the period of time evaluated was
used to calculate the total annual cost of deploying the
intervention. Under the low use scenario, it was judged
that one computer kiosk would be sufficient, while under
the high use scenario it was estimated that at least three
computer kiosks would be required to accommodate the
hypothesized level of utilization.
Costs of deploying the intervention in a kiosk in a
clinician’s office include the expense of computer purchase
and maintenance, estimated in an industry report as
$2,200 per year [35]. Other costs include a nominal licens-
ing fee charged by the software supplier to defray ongoing
costs of software distribution, costs of office space
estimated for a 8 foot by 8 foot office (64 square feet) using
a cost of $23.11 per square feet (including utilities and
maintenance based on average office costs for South
Florida in the United States reported in an industry publi-
cation [36]). Staff time required to demonstrate the inter-
vention and monitor patients under the low use scenario
was estimated to be one hour per day at the national
annual average medical assistant salary of $14.61 per hour
obtained from the web site of the US Bureau of Labor
Statistics, increased by 26.2% for fringe benefits and an
additional 44.8% for administrative overhead. For the
scenario under which 40% of office visits involved patient
education, it was assumed that for the larger number of
patients a larger number of computers and offices would
be needed (three compared to the one used for the alterna-
tive scenario). Computer and office-related costs were
therefore increased by a factor of three in calculating costs
in this scenario. Since it might be necessary for rural usersto travel to practitioners’ offices to use the intervention
when it is deployed as an information kiosk, transporta-
tion costs were calculated based on the average dis-
tance that rural patients travel to reach a specialist
physician [37] and the average cost per mile of automo-
bile travel in the US (59.6 cents) [38]. Transportation
costs were included for a supplementary scenario in
which all users were in rural areas and were required to
travel by automobile to a clinician’s office to use the
intervention. (These analyes are included in supple-
mentary tables included in Additional file 2.)
Costs associated with medications and clinical care
While generally desirable from a clinical and public health
point of view, an increase in patient adherence is likely to be
associated with greater medication costs since patients will
take their medications more regularly and consume more
medications. In order to evaluate the impact of the
computer-based intervention on total treatment costs, each
participant’s monthly medication costs was calculated using
data provided by participants on their medications and using
monthly average wholesale medication costs for 2012 in
estimates provided in a recent treatment guideline [39].
Total average monthly medication costs were calculated as
the total of costs for each participant assuming 70% adher-
ence (the level of adherence commonly found in studies of
adherence in this population [7]) divided by the number of
participants, with the increase related to the intervention
calculated as the 10% effect of intervention-related increase
in medication consumption for the proportion of patients
whose medication adherence increased.
Costs related to care were based on previously
established costs for all health care costs except anti-
retroviral medications (inpatient, outpatient, laboratory,
and non-HIV-related medications) for ranges of CD4
cell counts [30] adjusted to 2012 dollars. Changes in
costs related to changes in adherence were calculated
based on previously reported values derived from a com-
puter model of the relations among adherence, viral
load, and CD4 count [31]. As our sample size did not
provide a reliable way of establishing the effect of the
intervention of persons with lower ranges of CD4 counts
sensitivity analyses were used to evaluate a wide range of
possible changes in CD4 counts in response to the
intervention.
Costs and utilities related to change in adherence
Non-medication related costs related to health status
were calculated under four possible scenarios of change
in health status based on CD4 count (less than 50 cells/
mm3, 100–199, 200–349, 350–499, and greater than
500; see bottom half of Figure 2). For example, in the
“minimally effective” scenario (see Table 2) which
hypothesized the smallest intervention effect, it was
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50 would show a treatment effect resulting in their mov-
ing from the less than 50 group to the group with CD4
cells in the range of 51 to 200 (this 5% transition prob-
ability is represented in Figure 2 as p(t)x1, ie, the transi-
tion probability for the first possible change from one
group to another). Based on costs reported by Gebo
et al. [30], the per person decrease in annual medical
costs (excluding medications, but including inpatient,
outpatient, and laboratory costs) for the transition be-
tween these two groups would be $18,043 (the difference
between $33,007 for the first state, and $14,964 for the
new state; see lower portion of Figure 2). Change in
costs associated with the intervention’s effect was thus
calculated as 5% of this amount (again using the transi-
tion probability represented as p(t)x1); changes in per
person costs for each state (when scenarios assumed
transitions occurred for several groups) were averaged
across CD4 groups and used in subsequent calculations.
Better health resulting from improved adherence was
assumed to result in some participants being able to re-
turn to work. Issues related to return to work for per-
sons with HIV/AIDS are complex, including such
factors as loss of disability benefits including medical in-
surance with return to work, difficulties in finding child
care, as well as enhanced self-esteem from the return to
work [40,41]. Although with implementation of a return
to work program a substantial number of persons with
HIV/AIDS may be able to return to partial employment
[42], one study showed that only about 15% of patients
returned to full time work over two years [43]. In order
to account for the possible economic benefits of patients
returning to work, the effects of 15% of participants
returning to full-time work (based on estimates of salary
or wages for each person based on their educational at-
tainment) were included in analyses.
In a similar way, changes in health utilities were also
based on previously determined utility values [29] for
states defined by CD4 count (top half of Figure 2) and
the probability of a patient’s status changing in response
to the intervention. For example, the change in health
utility for a patient whose CD4 status changed from less
than 100 to the range of 100 to 199 would be 0.008 (the
difference in utility between the first and second states).
As with calculation of costs, the net change for health
utility was calculated as the product of the change and
the probability (p(t)xi) that patients would change
their status. Values were calculated for each possible
transition to a different health status, and an average
of amounts was used for calculating aggregate values.
The transition probabilities used in each of these
effectiveness-related scenarios are presented in Table 2.
In analyses it was assumed that the change modeled by
the transition probability would affect the given numberof participants for the period during which the interven-
tion was assumed to have an effect. In the analyses
presented here, this period was assumed to be six
months. In supplementary analyses evaluating the effects
of different durations of intervention effectiveness, the
period varied from one to 12 months. In all analyses, it
was assumed that the only effect of the intervention was
to increase the probability that a patient would make the
transition from a lower to a higher CD4 and that per-
sons with high CD4 levels probably also had high levels
of adherence and thus would show little or no response
to the intervention, as shown in the original study [15].
Although it is likely that in a clinical setting some
patients might make a transition from higher to lower
group, this possibility was not explicitly modeled.
The format of the intervention allows it to be made
available to potential users in several ways. As
developed, the intervention was presented to users on a
stationary computer; the intent was to allow for the
intervention to be implemented in a clinician’s office as
an information kiosk, with patients completing the inter-
vention in the physician’s office as part of routine care.
The intervention can, however, be deployed on a web
site that would allow much wider access by large num-
ber of patients. Another group of investigators has
presented cost data for a web-based adherence interven-
tion [44], and we used their estimates in calculating the
cost of deploying the computer-based health literacy ap-
plication so that it was possible to compare deployment
costs for several options. Costs of the web-based deploy-
ment were calculated for the same number of users as
employed in cost calculations for the clinical office
scenario as well as for a much larger number of users as
might be expected for a web-based application. For this
larger number of users, costs were held constant except
for advertising costs. Advertising costs were increased by
ten times (based on the assumption that ten time
increase in advertising would be required to reach the
necessary number of potential participants) to reflect the
need for greater publicity in order to ensure that a
substantially larger number of participants would use
the web-based intervention. The costs of deploying the
intervention on the Internet were calculated using the
same estimates of staff, server hosting advertising, and
technical support provided by Page et al. [44] for a web-
based adherence intervention. Analyses of annual costs
at two levels of utilization were calculated for the web-
based deployment across the same levels of effectiveness
used for the office or clinic based format (Table 4).
Effectiveness
Analyses showed that the magnitude of the intervention’s
effect was related to a patient’s baseline level of adher-
ence but averaged an increase of 10% [45] in patients
Table 4 Semiannual costs for web deploymenta
Low utilization (540 users) High utilization (1,620 users)
Project Coordinator $17,160 $17,160
Server Hosting $150 $450
Advertising $510 $5,100
Technical Support $10,398 $20,796
Total Costs $28,218 $43,506
Deployment Cost per User $52 $27
aCosts for low utilization scenario are drawn from Page et al. [44]. Costs for high utilization scenario are increased for server hosting, technical support, and
advertising to reflect greater server use and advertising to increase number of users.
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crease obtained in a study of a similar intervention
among elderly patients with memory impairments [46].
Participants with low levels of adherence at baseline
showed greater increases in adherence than those with
higher baseline levels. Because of lack of adequate data to
determine the effects of changes in medication adherence
on CD4 counts and thus on health utilities, sensitivity
analyses were completed for a range of possible levels of
effect. Scenarios were estimated as the percentage of each
group with a specific CD4 count which might increase
their CD4 counts so that they moved to the next higher
group under the scenarios presented in Table 2. It was
assumed that a proportion of the individuals with CD4
counts in the lower groups would have these levels due
to poor medication adherence and thus exposure to the
intervention would be more likely to result in changes in
adherence and health status. It was also assumed that
individuals with higher CD4 counts were more likely to
already have high levels of adherence and thus were less
likely to show a change in CD4 count in response to the
intervention.
Utilities
Health utilities are numeric quantities that represent the
value of life adjusted for health status. In their calcula-
tion, it is assumed that one year of life with lower health
is worth less to a patient than a year in perfect health.
The value of a year of life whose quality is reduced by
poor health might be represented by a value less than
1.00 [47]. A previous study had developed health utilities
in those with HIV infection related to ranges of CD4
counts [29]. In evaluating health utilities it was assumed
that an increase in medication adherence would result in
improved health as indicated by a higher CD4 cell count.
A net change in utilities for each CD4-defined group
was calculated as the product of the probability of a
change in a patient’s life quality utility and the probabil-
ity that their CD4 status would change in response to
the intervention. Changes for each category were
averaged to provide an overall net change in utility for
the intervention. As completed for cost estimates relatedto changes in CD4 count, sensitivity analyses were
completed to evaluate a range of potential effects of the
intervention on adherence. QALYs were calculated based
on changes in utilities as described above, making the
assumption that the effect of the intervention persisted
for six months. The widely-used value of $50,000 per
QALY was used to judge the intervention’s cost effect-
iveness, although we note that values ranging up to
$100,000 per QALY have been used in other studies and
that other authorities have argued that the actual cost
per QALY may be higher when it is evaluated in the
context of the cost of other interventions commonly
paid for by third party payers [48,49].Sensitivity analyses
In addition to the sensitivity analyses completed as
evaluation of the range of levels of intervention effective-
ness based on its effect patient health status (the four ef-
fectiveness levels described in Table 2), potential
variations in development and deployment costs were
also evaluated in sensitivity analyses by assessing the ef-
fect of a range of increases and decreases in develop-
ment costs when development costs were not reduced
by research-related amounts. These analyses are
reported in supplementary tables for this paper. As the
initial study of the intervention had only demonstrated
its effects over one month, cost per QALY was evaluated
for each deployment scenario over four possible
durations of effectiveness, three, six, nine, and twelve
months. These times were chosen based on follow-up
studies of other adherence interventions [27,50,51] that
have shown that adherence-oriented educational inter-
vention effects may persist up to 18 months.Results
Adjusted development costs are presented in Table 3.
Total direct costs for development were $204,704 which,
combined with administrative costs yields a total project
cost of $296,411. For the 124 participants, this resulted
in a development cost per participant of $2,390. Assum-
ing an average increase of 10% adherence for each
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each 1% increase in adherence.
As the effect of the intervention was assumed to persist
for six months, deployment cost calculations are based on
this period. Semiannual costs of deploying the intervention
in a clinician’s office under two utilization scenarios are
presented in Table 5. The cost of providing the intervention
(exclusive of development costs) to each patient under the
low and high utilization scenarios was $60, for a cost per 1%
increase of $6. Costs of deploying the intervention on the
Internet under two utilization scenarios are presented in
Table 4. For the same number of users as in the high
utilization scenario in a clinician’s office (540 users
semiannually), the cost per user for Internet delivery is $52
with a cost of $5 for 1%. For a larger number of semiannual
users, however, costs drop substantially even with an in-
crease in advertising costs, to $27 per user, and a cost of $3
for each 1% increase.
Cost utility analyses for the information kiosk deployment
strategy are presented in Table 6. Taking into account all
costs and benefits, including increase in medication costs
and decrease in other healthcare costs yielded a net cost of
the intervention for the minimally effective scenario of
$255,032 for a cost per QALY of $67,469. The cost per
QALY declines with increases in intervention effectiveness
and a larger number of users. The highest effectiveness level
for the low utilization deployment scenario is associated
with a net cost savings of $15,726, while for the high
utilization scenario all costs per QALY are less than $20,000
or are negative, indicating a net cost savings.
Analyses for deployment of the intervention on the
Internet are presented in Table 7. While the cost per
QALY is positive for scenarios with low levels of interven-
tion utilization, higher levels of effectiveness with higher
levels of utilization resulted in net cost savings. For the
high utilization condition, costs per QALY at all levels
of effectiveness were less than $50,000 and in several
cases were associated with net cost savings (values in
parentheses in Table 7).Table 5 Semiannual costs for information kiosk deployment (
Computer per year (includes electrical consumption, maintenance, software)
Licensing
Office space @ $23.11 / sq ft
Staff support (medical assistant)
Loss of salary and wages from office visit
Total cost of deployment
Total users for six months
Deployment cost per patientThresholds and sensitivity analyses
Thresholds for development costs that would result in a
value of $50,000 per QALY were calculated for each
scenario at the moderate effectiveness level. For the office
kiosk low utilization scenario with 540 patients over six
months, 122% of adjusted costs resulted in a value of
$50,000 per QALY. For the office high utilization scenario,
267% of adjusted costs were related to the target cost per
QALY. For the low utilization Internet deployment scenario,
a decrease in costs to 77% of the total were associated with
the target cost per QALY, while for the high utilization
Internet scenario, costs inflated to 288% were related to tar-
get cost per QALY. Thus with the exception of the low
utilization Internet deployment scenario, the conventional
value of $50,000 per QALY was associated with increases in
development costs over the unadjusted values obtained from
the grant budget.
Sensitivity analyses using unadjusted costs that evaluated
possible effects of a range of increases or decreases in devel-
opment costs from 50% of the unadjusted value to 150% of
the value costs were completed. These showed that
increases in development and deployment costs affected
costs per QALY so that for low levels of effect, short dur-
ation of effect cost per QALY values were very large – in ex-
cess of $1,000,000 (see Additional file 2). Cost per QALY for
the 6 months’ duration used in these analyses showed that
values ranged from $39,805 for the minimally effective
scenario with costs at 50% of original to a $58,114 for the
highly effective scenario evaluated at 150% of original costs
(Additional file 2). Addition of costs of transportation
(round trip travel by car to a doctor’s office in order to use
the intervention) for rural patients resulted in similar values,
again very large for short durations of effectiveness and cost
inflations and most values lower for longer durations of ef-
fectiveness (see Additional file 2).
Summary
Relations among effectiveness, number of users, and
duration of intervention effectiveness are illustrated inoffice or clinic)
Low utilization (540 users) High utilization (1,620 users)
$2,200 $6,600
$50 $150
$8,874 $26,623
$3,181 $9,543
$18,202 $54,607
$32,507 $97,522
540 1620
$60 $60
Table 6 Semiannual net intervention costs and cost per QALY for kiosk deployment by efficacy scenarios
Low utilization (540 users) High utilization (1,620 users)
Cost Minimally Slightly Moderately Highly Minimally Slightly Moderately Highly
Increase in medication costs $7,635 $9,183 $30,611 $53,569 $22,958 $27,550 $91,833 $160,707
Decrease in IP/OP/other treatment costs $60,895 $65,450 $152,861 $297,424 $182,685 $196,349 $458,582 $892,272
Loss of salary and wages from participation $18,202 $18,202 $18,202 $18,202 $54,607 $54,607 $54,607 $54,607
Increase in salaries and wages resulting from return
to work
$20,644 $24,722 $82,575 $144,506 $61,931 $74,317 $247,725 $433,518
Net cost of intervention (includes development and
deployment)
$255,032 $247,879 $124,094 ($59,443) $172,275 $150,816 ($220,540)a ($771,150)
Cost per user $472 $459 $230 ($110) $106 $93 ($136) ($476)
Cost per QALY $67,469 $65,577 $32,829 ($15,726) $15,192 $13,300 ($19,448) ($68,003)
aNumeric values in parentheses indicate negative values, i.e., net cost savings for the intervention in this scenario.
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cost effective for the high utilization office kiosk and
Internet scenarios at three months and for all scenarios
at six months. Longer durations of effectiveness were
associated with net cost savings for both office-based
scenarios and the high utilization Internet scenario. For
very short durations of effectiveness such as one month,
cost per QALY was very large (often greater than
$1,000,000). The cost-effectiveness of the intervention
thus is closely related to the time during which its
effects persist, most likely due to the ongoing accrual of
cost savings and improved quality of life over time.
These accruals of savings over time offset the initial
development costs, emphasizing the importance of
the intervention’s duration of effect in understanding
the relation of costs to the interventions overall cost
effectiveness.
Discussion
The purpose of this paper was to evaluate the relation of
the costs of developing and deploying a computer-
delivered adherence intervention to its effects in decreasing
treatment costs and improving health status. A specific
goal was to evaluate whether the initial high costs ofTable 7 Semiannual intervention costs and cost per QALY for
Low utilization
Cost Minimally Slightly Mo
Increase in medication costs $15,305 $18,367 $
Decrease in IP/OP/Other treatment costs $121,790 $130,989 $
Loss of salary and wages from participation $18,202 $18,202 $
Increase in salaries and wages resulting from
return to work
$20,644 $24,722 $
Net cost of intervention (including development
and deployment)
$215,703 $205,526 $
Cost per user $399 $381
Cost per QALY $57,064 $54,372
aNumeric values in parentheses indicate negative values, i.e., net cost savings for thdevelopment of such an intervention are offset by its
benefits over time. The actual costs of developing the inter-
vention and estimates of the costs of participants’
medications based on their actual medication regimens
were used in analyses. Changes in costs related to other
aspects of care (inpatient and outpatient care; laboratory;
non-HIV-related medications) were estimated from an-
other report [30], as these were not recorded for current
study participants. Sensitivity analyses assessed the relation
of outcomes to a range of costs, intervention effects, and
intervention durations. Even with a moderate probability
of change in CD4 count (mean 5% change in CD4
category) for a small number patients (low utilization
office-based deployment scenario), the computer-delivered
intervention was cost-effective as judged by the conven-
tional benchmark of $50,000 per QALY (cost per QALY =
$32,829; Table 6). With higher probabilities of effects and
wider deployment via the Internet, use of the intervention
would result in net cost savings.
These results are similar to those of other analyses that
have reported net cost savings from interventions to en-
hance adherence. Sansom et al. [19] showed that inten-
sive case management for adherence produced net cost
savings from decreased service utilization, although thisweb deployment by efficacy scenarios
(540 users) High utilization (1,620 users)
derately Highly Minimally Slightly Moderately Highly
61,222 $107,138 $45,916 $55,100 $183,655 $321,414
305,721 $594,848 $365,371 $392,698 $917,163 $1,784,543
18,202 $18,202 $54,607 $54,607 $54,607 $54,607
82,575 $144,506 $61,931 $74,317 $247,725 $433,518
15,757 ($289,385)a $13,138 (17,393) ($586,699) ($1,502,124)
$29 ($536) $8 ($11) ($362) ($927)
$4,169 ($76,557) $1,159 ($1,534) ($51,737) ($132,462)
e intervention.
Figure 3 Cost per QALY for deployment scenarios and duration
of effect. Note: For each deployment scenario, the cost per QALY at
a moderate level of effectiveness for four possible durations of
interventions effect. Black line marks the $50,000 cost per QALY
commonly used to assess whether an intervention is considered
cost effective.
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count. Our conclusions are also consistent with those of
Goldie et al. [52] who argued that even adherence
interventions with modest effects may be cost effective,
and Freedberg et al. [53] who showed that a nurse-led
adherence intervention was cost-effective with a cost per
QALY of $14,100 compared to usual care. Further,
Braithwaite et al. [31] showed via a sophisticated com-
puter model of the effects of adherence on health status
and costs in persons treated for HIV that a modestly ef-
fective intervention associated with an absolute risk re-
duction of 4% for poor adherence costing less than
$1,000 per user would be cost effective (Table 6). Ana-
lyses presented here show that even with conservative
projections of intervention effectiveness and with small-
scale deployment, cost per user estimates for the inter-
vention was less than $500 and in many instances was
associated with net costs savings (Table 6).
Results thus emphasize the importance of the duration
of the intervention’s effect in determining its cost effect-
iveness. In these analyses, a range of effect durations was
used in sensitivity analyses as we lacked specific infor-
mation on how long the effects of the intervention
would persist. At very short durations of effectiveness,
the cost per QALY of the intervention was unacceptably
high, but with greater durations of effect cost savings
and improved quality of life accrue, yielding a more fa-
vorable cost per QALY (less than $50,000). For analyses
presented in Tables 6 and 7, a six month duration was
assumed based on other data showing that the dura-
tion of effect of education-oriented adherence inter-
ventions may range up to eighteen months [50,51].
Further, analyses in a meta-analysis of trials of adherenceinterventions showed no marked deterioration in inter-
vention effects over time after adherence interventions
[27]. These findings highlight the need for better data on
the impact of adherence interventions on actual adher-
ence over time. As noted in a review of adherence
interventions for HIV [54], many studies of adherence
interventions do not include follow-up data. Given the
relation of cost-effectiveness to duration of intervention
effect found in our current analyses, it is clear that more
information is needed on how long an intervention may
be effective and on strategies to promote adherence over
time.
Limitations of this study should be acknowledged. As
with any cost-effectiveness or cost-utility analysis, it was
necessary to make several assumptions about the effects
of the intervention on patient medication adherence and
on the effects of adherence on patient health. To address
these issues, we based analyses on other researchers’
models of the relation of adherence to viral load and
CD4 count [31], used conservative estimates of the
health utilities associated with various levels of CD4
count [29], and used sensitivity analyses taking into ac-
count a range of possible levels of intervention effective-
ness. We depended on the convention of judging the
cost effectiveness of an intervention based on the criter-
ion of more or less than $50,000 per QALY although we
note that other investigators have argued for a range of
values from $50,000 to $100,000 or more [48,49].
Others have shown that computer-delivered interventions
may be cost-effective in health care. McCrone et al.
[55], for example, showed that computer-delivered cog-
nitive behavioral therapy could be a cost-effective strat-
egy to deliver depression treatment in primary care,
and Smith et al. [56] showed that a computer-delivered
intervention for smoking cessation was also cost effect-
ive. The results presented here are also consistent with
other studies that have shown that in spite of their de-
velopment and deployment costs, computer-delivered
interventions can provide good value in terms of health
outcomes in relation to costs. This may be particularly
relevant in delivery of services to persons in rural areas;
other researchers have shown that telephone-delivered
interventions may be effective in this population
[57,58]. Analyses that included increased costs of trans-
portation for rural patients to travel to a clinician’s
office to use the intervention yielded cost per QALY
estimated that were only slightly different from those
found when these costs were not included. Analyses
thus show that method and scope of deployment of
an intervention can substantially affect its cost effec-
tiveness, as the Internet-based deployment condition,
with a large number of users, resulted in the greatest
net cost savings. An additional limitation is that the
results presented here assume that the effects of the
Table 8 Summary of advantages and disadvantages of intervention formats
Delivery format Advantages Disadvantages
Clinician • Personal • Time required
• Information readily tailored to patient concerns or characteristics • Oral presentation related to limited learning
• Clinicians may not have therapeutic skills• Interactive
• Opportunity for questions and follow-up
Information
Kiosk
• Information can be computer tailored • Less personal
• Interactive • Less clearly tailored
• Multimedia may enhance patient interest and understanding • Less opportunity for follow-up
• Requires less clinician time • Demands some computer skills
• Can provide more information in a longer intervention • Requires space and computer support
• Can provide therapeutic interventions for depression and substance abuse
Internet Based • Information can be computer tailored • Less personal
• Less clearly tailored
• Much less opportunity for follow-up questions• Interactive
• Requires computer and high-speed Internet
access
• Multimedia may enhance patient interest and understanding
• Requires less clinician time
• Can provide more information in a longer intervention
• Can provide therapeutic interventions for depression and substance abuse
• Can be available on demand at times when patients are available or
motivated.
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demonstrated in the original study. Although we note
that other similar adherence interventions may have
effects that persist for as long as one year [27], it should
be acknowledged that this assumption is not directly
supported by our data. Further, it should be noted that
some of our cost estimates, notably the cost of office
space, may vary widely by geographic locale.
Another important issue is the extent to which the
effects of any intervention for adherence delivered over
the Internet would mirror those obtained from the office-
based information kiosk format. Although the content
and types of interactions would be virtually identical, the
context in which the intervention is completed may have
an unknown impact on outcomes. Further, while patients
may be more likely to complete this type of intervention
when it is recommended in the clinician’s office, they may
be less likely to spontaneously use it when it is provided
over the Internet. It is noted that searching for health in-
formation is a common use of the Internet even among
mobile phone users [59] and that in a recent article the
director of the National Institutes of Health, Francis
Collins, cited the development of health applications as a
research priority [60]. Additional information on patients’
use of Internet-based health applications is thus needed.
Still another issue is related to the demands the inter-
vention makes on motivation and attention on the part
of affected patients, some of whom may be affected by
mental health and substance abuse problems as well aseconomic and housing instability. During the develop-
ment of the intervention, a large number of our
participants were affected by these issues and still were
able to complete not only the intervention but also a
demanding battery of cognitive and psychosocial
measures. As noted in the introduction, the intervention
addressed the possible problems that might have been
encountered by extensively testing the intervention prior
to deployment with potential users.
Given the potential advantages of computer-delivered
interventions, it is reasonable to question why they are
not more widely used. Shakeshaft and Frankish [61] also
note the possible advantages of computer-delivered
interventions in prevention, and suggest several factors
that may affect their adoption. They indicate that a com-
bination of lack of understanding of existing evidence
for effectiveness, perceived high cost of implementing
the intervention, and concerns about the impact of less
personal interventions may reduce health care providers’
enthusiasm for computer-delivered interventions. In our
own clinic, we have encountered concerns about lack of
space, the potential for lengthening patient visits thereby
decreasing clinic efficiency, and the initial cost of
computers in discussions of deploying computer-based
interventions. It is thus likely that even with demonstra-
tion of cost effectiveness, deployment of the intervention
as an information kiosk may face resistance.
While deployment of the intervention on the Internet
may address factors related to the clinic, it will have its
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most effective ways to ensure that patients become
aware of the intervention, encouraging them to complete
it, and the possibility that the patients most in need of
the intervention may not have high-speed access to it on
the Internet. The intervention’s multimedia and inter-
active format make it difficult to deploy on standard cel-
lular telephones, most of which lack the types of screens
and processors that could render the material on the
telephone screen. Although the intervention can be
viewed on a smartphone, only the increasing penetration
of high speed data access and smart phones will allow
the intervention to be easily accessed by persons without
Internet-connected computers.
Conclusions
These analyses show that in spite of higher initial devel-
opment costs than for clinician-delivered interventions,
a computer-delivered intervention may be a cost effect-
ive strategy for improving medication adherence in per-
sons treated for HIV. The analyses also show that
depending on the effectiveness of the intervention and
on how widely it is deployed, its use may result in net
cost savings. Each possible delivery format for adherence
education has potential benefits. As summarized in
Table 8, clinician-delivered interventions may be the
most flexible and individually-tailored but may suffer
from the time press of daily clinical practice. Electronic
delivery of adherence interventions may still be tailored
but less flexibly so. Electronic delivery may provide more
detailed information in a multimedia format, but provide
patients with less opportunity to ask questions. Elec-
tronic delivery formats raise the possibility that clinicians
will actually spend less time on adherence with patients,
although some evidence suggests that patients provided
with access to electronically-delivered information may
be more active participants in medical encounters [18].
Results of this study may be useful in supporting the de-
velopment and deployment of other computer-delivered
interventions. In light of the great need for better
interventions to improve medication adherence and the
lack of trained personnel to deliver them, a computer-
delivered intervention may be helpful in addressing need
while making small demands on treatment resources.
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